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Uncontrolled interactions of gene vectors and drug carriers
in and with an in vivo environment pose serious limitations
to their applicability. In order to reduce such interactions we
have designed, synthesized and applied novel copolymers
of poly(ethylene glycol) and reactive linkers which are deriv-
atized with anionic peptides after copolymerization. The
anionic copolymer derivatives are used to coat positively
charged nonviral gene vectors by electrostatic interactions.
The copolymer coat confers to polyelectrolyte colloids of
DNA and polycations steric stabilization in their minimal size
and prevents salt- and serum albumin-induced aggregation.
Keywords: nonviral gene vectors; opsonization; protective copolymers; steric stabilization; complement activation; gene
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Introduction
Although nonviral gene vectors are efficient in vitro as
well as in some animal models, their uncontrolled and
often undefined interactions under physiological con-
ditions still represent a major obstacle to their application
in gene therapy. In particular, it has been shown that
nonviral gene vectors or their constituents interact
strongly with blood components such as the complement
system1 and other blood proteins.2 Such opsonization
alters the physico-chemical characteristics of vectors, may
interfere with vector targeting and is of concern if vectors
are to be applied in humans. Consequently, one major
objective in nonviral vector development is to devise vec-
tors which are inert in the in vivo environment during
the delivery phase. Gene delivery in vivo comprises an
extracellular and an intracellular delivery problem where
solutions to one part must be compatible with the
requirements of the other. To overcome some of the intra-
cellular barriers, nonviral vectors are designed to mimick
important features of viral cell entry. Synthetic modules
for receptor targeting, DNA binding and compaction and
intracellular release are assembled with DNA in a step-
wise manner by electrostatic interactions. In liposome3
and nanoparticle technology,4 poly(ethylene glycol) has
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Furthermore, complement activation and the interaction with
serum proteins are drastically reduced or abolished in con-
trast to unprotected DNA complexes. The designed vectors
are compatible with the intracellular steps of gene delivery
and can even enhance transfection efficiency as demon-
strated with various adherent and nonadherent cell lines in
culture. The synthetic concept is amenable to the principles
of combinatorial chemistry and the copolymeric products
may be applicable beyond gene delivery in targeted drug
delivery. Gene Therapy (2000) 7, 1183–1192.
been used to confer to these drug carriers the desired
stability during the extracellular delivery phase. For the
same purpose, PEG has been grafted covalently to pre-
assembled polycation–DNA complexes.2 It was the aim
of the work presented here to develop a new class of pro-
tective copolymers (PROCOPs) based on PEG which are
assembled with nonviral gene vectors by electrostatic
interaction (Figure 1). Such polymers are derived from
PEG by copolymerization with amino acids, amino acid
derivatives or with peptides and optional subsequent
derivatization. The synthesis can be carried out by estab-
Figure 1 Preparation of copolymer-protected gene vectors (COPROGs).
A preformed lipoplex or polyplex with excess positive charge is incubated
with a negatively charged peptide–PEG copolymer resulting in a surface
layer of PEG loops. The copolymer backbone can be reacted with receptor
ligands and other effector molecules (symbolized by asterisks).
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lished methods of peptide chemistry. In this communi-
cation we describe one class of PROCOPs which is syn-
thesized by coupling anionic peptides to a reactive
copolymer backbone. We show that copolymers obtained
with the peptides YE5C ([Ac-YEEEEE]2K-ahx-C; ahx = 6-
aminohexanoic acid, Ac = acetyl) and INF7 (GLFEA
IEGFIENGWEGMIDGWYGC5), stabilize polyplexes at
small size and protect from complement activation and
opsonization. Finally, we demonstrate that protecting
nonviral vectors with these copolymers is compatible
with the cellular steps of gene delivery.
Results
Copolymer synthesis
Standard peptide chemistry was applied to synthesize
3-(2¢ -thio-pyridyl)-mercaptopropionyl-glutamic acid (com-
pound 3, Figure 2a) as a building block for copolymeriz-
ation with commercially available diamino-PEG of vari-
ous molecular weights. The polymerization reaction
yields a strictly alternating copolymer backbone with
reactive side chains for further derivatization. The
degrees of oligomerization of the main products (50% of
total product) were 6 to 7 as calculated from the retention
volumes on a calibrated Superdex 75 column. Minor
higher molecular weight byproducts were separated
using the same column. The calculated degrees of poly-
merization were consistent with the observed differences
in retention volumes before and after coupling effector
peptides to the reactive copolymers. The effector peptides
in this study were YE5C, and INF7,5 resulting in the pro-
ducts P3YE5C, P6YE5C and P3INF7, P6INF7, respectively
(Figure 2b; P3 refers to PEG3400-derived, P6 refers to
PEG6000-derived products).
The synthetic concept is amenable to combinatorial
chemistry by systematic variation of the chain length of
the PEG macromonomer, the type of linkage in the poly-
mer backbone (eg amide versus ester), the overall degree
of polymerization and the peptide type as well as its
charge. Polymers appropriate for gene delivery can be
selected using aggregation assays, complement activation
and gene transfer assays in 96-well plate format such as
described below.
PROCOPs P3INF7 and P6INF7 display pH-dependent
membrane-destabilizing activity
The membrane-destabilizing activities of influenza and
related peptides are examined using an erythrocyte lysis
assay.5 The purification of P3INF7 and P6INF7 by size
exclusion chromatography yielded fractions that were
substantially more active in the erythrocyte lysis assay
than the starting peptide INF7 at pH 5. At pH 7.4 all
products were inactive (Figure 3).
PROCOP-coated polyplexes are small and stable
colloidal particles
Polymer-protected DNA complexes were assembled
according to Figure 1. Binding of PROCOPs to preas-
sembled polyplexes and lipoplexes was demonstrated in
direct and indirect ways. Biospecific interaction analysis
(BIAcore) experiments demonstrated that PROCOPs bind
to lipoplexes and polyplexes (data not shown). Zeta
potential determinations confirmed binding in that the
highly positive zeta potentials of lipoplexes and poly-
Figure 2 (a) Synthesis of the reactive copolymer backbone. 3-(2¢ -thio-
pyridyl)-mercaptopropionyl-glutamic acid (3) is derived in a standard car-
bodiimide-activated coupling reaction from t-butyl-protected glutamic acid
and 3-(2¢ -thio-pyridyl)-mercaptopropionic acid (1). After deprotection,
product (3) is copolymerized with diamino-PEG upon DCC activation
in situ. (b) The purified thiol-reactive polymer backbone is reacted with
negatively charged cystein-containing peptides. INF7, sequence GLFEAI-
EGFIENGWEGMIDGWYGC; YE5C, sequence (Ac-YEEEEE)2K-ahx-C,
ahx = 6-aminohexanoic acid, Ac = acetyl.
plexes decreased as a function of the amount of PRO-
COPs added to preassembled DNA complexes (Figure 4).
At no point of lipoplex or polyplex composition solubility
problems were encountered such as observed with DNA
complexes in the absence of PROCOP at electrostatic neu-
trality. PROCOP addition to preassembled polylysine or
PEI polyplexes as well as DOTAP-cholesterol lipoplexes
does not dissociate these gene vectors as judged by a gel
retardation assay (data not shown). Polyplexes remain
tightly condensed as is demonstrated by electron
microscopy (Figure 5) and dynamic light scattering
(Table 1). Both determination methods consistently indi-
cated that copolymer-protected gene vectors (COPROGs)
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Figure 3 Erythrocyte lysis assay (citrate buffer, pH 5, filled symbols).
Quantities of polymers were applied so that equal amounts of peptide INF7
are compared. X-axis: mmolar concentration of peptide in the assay mix.
No leakage is observed at pH 7.4 (open symbols).
Figure 4 Zeta potentials of COPROGs. Purified and unpurified PEI–
DNA complexes (initial N/P = 8) and DOTAP/cholesterol (charge ratio
5) lipoplexes with increasing amounts of P3YE5C or P6YE5C added
(amounts of PROCOP are given in equivalents of negative charges rela-
tive to the negative charges of DNA in the complex). Shown are mean
values of at least four measurements with error bars too small to be seen.
Gene Therapy
Figure 5 Electron micrographs of COPROGs. Bars indicate 100 nm. (a)
PEI–DNA, N/P = 8, in the presence of 3 charge equivalents of P3YE5C;
(b) in the presence of 2 charge equivalents P3YE5C and 1 mg/ml BSA
after overnight incubation; (c) DOTAP/cholesterol–DNA lipoplex charge
ratio (– ) 5; (d) the same in the presence of 5 equivalents P6YE5C. All
complexes were prepared in 20 mM HEPES pH 7.4.
Table 1 Particle sizes in nm determined by dynamic light scat-
tering (DLS) in the absence and in the presence of 150 mm sodium
chloride or 1 mg/ml BSA
20 mM HEPES +150 mM +BSA 1
pH 7.4 NaCl mg/ml
PEI–DNA 47.9 – 3.8 .2000 within Precip
(n = 9) 2 h
PEI–DNA filt 58.0 – 7.0 .2000 within Precip
(n = 3) 2 h
PEI–DNA + 2 35.3 Slow aggreg 33.2
equiv P3YE5C (n = 2) 81.90 – 6.2 (n = 2)
(n = 11)
162.5 – 1.8
(n = 5; o/n)
PEI–DNA + 2 50.9 – 5.3 43.0 – 4.0 41.6 – 4.6
equiv P6YE5C (n = 10) (n = 8) (n = 4)
pL–DNA 50.0 – 4.6 .2000 within ND
(n = 9) 1 h
pL–DNA + 6 72.5 – 3.3 86.3 – 2.6 ND
equiv P3INF7 (n = 4) (n = 6)
pL–DNA + 6 61.7 – 0.6 ND ND
equiv P6INF7 (n = 13)
ND, not determined; o/n, overnight.
prepared from PEI and pL are extraordinarily small par-
ticles with a remarkable monodispersity (22.7 – 4.3 nm
nm by electron microscopy of PEI–DNA, Figure 5a; 50–
70 nm for pL–DNA by DLS, Table 1). According to an
estimate published by Blessing et al6 the observed struc-
tures are most likely monomolecular DNA complexes (ie
one DNA molecule per particle) in the case of PEI-DNA.
Very small particles (,50 nm) can easily be achieved
with PEI-DNA in salt-free buffer of appropriate pH even
in the absence of PROCOPs. However, these unprotected
complexes aggregate immediately upon salt or BSA
addition (sodium chloride addition to a final concen-
tration of 150 mm; BSA final concentration 1 mg/ml, see
below). In contrast, copolymer-protected polyplexes are
sterically stabilized (37.0 – 6.4 nm by electron
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free, as well as in salt-containing buffer and even in the
presence of BSA the initial small and monodisperse par-
ticle size is retained upon storage of fully assembled
COPROGs at 4 ° C for at least several days. Contrary to
polyplexes, the shape of DOTAP/Chol lipoplexes
changes dramatically upon PROCOP addition. Extended
tubular structures are formed in salt-free buffer
(Figure 5d) and the lipoplexes aggregate upon salt
addition.
PROCOPs prevent opsonization of nonviral gene
vectors
From previous studies it was known that during PEI–
DNA complex formation excess PEI is only loosely asso-
ciated with DNA so it can be removed by ultrafiltration
using Centricon-100 filter devices (PE and J-SR, unpub-
lished results). We examined ultrafiltrated and unpur-
ified PEI–DNA complexes for their susceptibility to
opsonization. In typical experiments 40–60% of the
applied PEI was removed by ultrafiltration when com-
plexes were formed at an N/P (nitrogen/phosphate)
ratio of 8, while 80–90% of the initial amount of DNA
were recovered as purified PEI–DNA complex in the
retentate. As expected from the molecular weight cut-off
of the filter membrane, no DNA was found in the filtrate.
Particle sizing by electron microscopy and dynamic light
scattering indicated a slight increase in particle size upon
filtration (43.6 – 4.4 nm by EM, not shown; 58.0 – 7.0 nm
by DLS, Table 1).
At concentrations below those prevailing in serum
(which are 35–50 mg/ml), BSA can be used as a probe to
assess opsonization of polyplexes. For both purified and
unpurified PEI–DNA complexes binding of saturating
amounts of bovine serum albumin manifests itself in a
reduction of the zeta potential from around +50 mV to
around - 16 mV. Depending on the ratio (w/w) of poly-
plex to BSA, visible aggregation (opalescence) and pre-
cipitation are observed. For a PEI–DNA concentration of
40 mg of DNA per milliliter, the aggregation and precipi-
tation range extends to about 5 mg/ml BSA, while at
higher BSA concentrations the polyplex stays in solution
(with BSA bound to its surface). If purified PEI poly-
plexes are coated with PROCOPs (3 charge equivalents of
P3YE5C or P6YE5C), the zeta potential remains at around
- 6 mV to - 7 mV upon BSA addition and aggregation and
precipitation are prevented, indicating that no BSA binds
to the vector. For unpurified PEI polyplexes, PROCOPs
do prevent BSA-induced aggregation, however, the zeta
potential is reduced to - 26 mV upon BSA addition, indi-
cating BSA binding due to incomplete protection.
Purified and unpurified (not shown) PEI polyplexes
(N/P = 8) activate the complement system (Figure 6a and
b). If purified polyplexes are coated with PROCOPs,
complement activation is inhibited dependent on the
amount of PROCOP added to the pre-assembled DNA
complex. PROCOP P6YE5C (prepared from PEG6000,
Figure 6b) is more efficient in this respect than P3YE5C
(PEG3400) (Figure 6a). In the same concentration range
unpurified PEI polyplexes are protected to some degree
but still display complement activation according to the
hemolytic assay (data not shown). Polylysine polyplexes
are protected from complement activation by the influ-
enza peptide PROCOP P6INF7, again dependent on the
amount PROCOP present (Figure 6c).
Complement activation is just one aspect of opsoniz-
ation. Therefore, surface plasmon resonance measure-
ments7 (BIAcore technology) were used to assess directly
general serum protein binding to DNA complexes. Whole
serum was coupled to a CM5 research grade sensor chip
by EDC/NHS activation. This sensor chip was examined
for binding of PEI–DNA complexes in the presence and
in the absensce of PROCOPs (Figure 7). While unprotec-
ted PEI–DNA complexes bound avidly to the serum-
loaded chip, PROCOP P3YE5C reduced binding con-
siderably and even more so did PROCOP P6YE5C dem-
onstrating the protecting capacity of both polymers con-
sistent with the results of the complement activation
assay where the same order of protecting capacity was
found.
PROCOPs are compatible with transfection and
promote vector targeting in cell culture
Transfections were carried out with adherent (NIH-3T3,
HepG2 and MDA-MB435S) and non-adherent (K562) cell
lines in serum-containing medium. The dependence of
transfection efficiency on the presence of PROCOPs was
examined with PEI8 and pL polyfection as well as
DOTAP/cholesterol9 and lipofectamine lipofection. Para-
meters such as the presence or absence of a receptor
ligand (transferrin; K562 cells), the charge ratio and salt
concentration were varied. COPROGs are essentially as
effective in in vitro gene delivery as their ‘naked’ ana-
logues depending on COPROG formulation. For PEI
polyplexes some inhibition is observed at the lower N/P
ratios (4 and 6) while at the higher charge ratios PRO-
COPs can increase transfection efficiency by about two-
fold, if complexes are prepared in salt-free buffer and up
to 10-fold if prepared in HBS (Figures 8 and 9). If trans-
ferrin as a receptor ligand is present in the DNA complex,
a pronounced synergistic enhancing effect of PROCOPs
is observed (Figure 10a; five-fold enhancement in the case
of hTf-PEI–DNA compared to PEI–DNA without PRO-
COP, up to 20-fold enhancement in the presence of
P3YE5C). Purification of PEI polyplexes by ultracentri-
fugation hardly affected transfection efficiencies (slight
enhancements were observed K562, HepG2 cells and
NIH-3T3 cells, Figure 9). Complexes were generally more
effective if prepared in salt-containing buffer (Figure 9,
hatched bars). If the PROCOP is synthesized with the
influenza peptide INF7 as the pending side chain it con-
fers protection from aggregation and opsonization to a
polyplex and due to the endosomolytic activity of this
membrane-destabilizing peptide class,5 transfecting
activity to otherwise ineffective polyplexes. This is dem-
onstrated by a transfection of the adherent cell line MDA-
MB435S with polylysine–DNA that has been coated with
P3INF7 (Figure 10b).
Discussion
Surface charge, particle size and colloidal stability are
interdependent physical characteristics of nonviral gene
vectors with a strong impact on their biological proper-
ties including their efficiencies in gene delivery. The
excess positive charge of lipoplexes and polyplexes,
which is required for full DNA compaction and nuclease
resistance, implies strong interactions with solutes (eg
blood proteins,10 erythrocytes2) and the extracellular
matrix11,12 under in vivo conditions. The mostly undesired
consequences can be unintentional vector targeting,
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Figure 6 Complement activation by COPROGs. Purified PEI–DNA (initial N/P = 8) with increasing amounts of P3YE5C (a) and P6YE5C (b). (c)
pL170-DNA (charge ratio – = 6.3) with increasing amounts of P6INF7. j, ‘naked’ DNA complexes; s, 1 charge equivalent P3YE5C (a), P6YE5C (b),
4.1 charge equiv. P6INF7 (c); d, 2 charge equivalent P3YE5C (a), P6YE5C (b), 8.3 charge equivalents P6INF7 (c); g, 3 charge equivalents P3YE5C
(a), P6YE5C (b), 12.4 charge equivalents P6INF7 (c). Complement serum is incubated with increasing amounts of the DNA complex under consideration
(x-axis) resulting in consumption of complement proteins if complement activation occurs. As a consequence decreasing CH50 values are observed. The
lower the percentage of CH50max the higher complement activation. CH50 values describe the particular dilution of serum which leads to lysis of 50%
of the sheep red blood cells in the assay. For details see Ref. 1.
Figure 7 Biospecific interaction analysis of PEI polyplex–serum interac-
tion in the presence and absence of PROCOPs. PEI–DNA complexes
(N/P = 8) coated with the indicated amounts of PROCOPs were injected
twice for 4 min (arrows) followed by washes with running buffer until
the signal stabilized (flow rate of 5 ml/min). Binding to the serum-loaded
sensor chip results in increasing resonance units (RU, y-axis). The time
scale over the total duration of each the experiment is 1200 s (x-axis).
Left, P3YE5C-coated complexes; right, P6YE5C-coated complexes (overlay
sensograms). Reduction of binding by increasing amounts of PROCOPs
is evident from decreasing response signals. The loading signal for naked
complexes (‘0 equiv’) does not reach a plateau due to continued aggre-
gation in the presence of salt during injection.
complement activation,1 vector inactivation12 and clear-
ance by the reticulo-endothelial system. Consequently,
recent efforts in vector development have focussed on
understanding and controlling the mentioned critical
parameters. Analogous to what has been explored in
drug delivery with nanoparticles4 and liposomes,3
poly(ethylene glycol) has been coupled covalently to pre-
Gene Therapy
Figure 8 Gene transfer studies, HepG2 cells. Dependence of PEI 25 kDa
polyfection (unpurified complexes) on the amount of P3YE5C (a) and
P6YE5C (b) at various charge ratios. Shown are mean values of transfec-
tions carried out in triplicates, error bars indicate standard deviation.
Complexes were prepared in 20 mm HEPES pH 7.4 and adjusted to 5%
glucose before addition to cells.
assembled vectors or their cationic component in order
to confer the desired stability.2,13
As an alternative approach, we have developed a class
of anionic copolymers which are attached to pre-
assembled gene vectors by electrostatic interaction
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Figure 9 Transfections of K-562, HepG2 and NIH 3T3 cells. Dependence of PEI 25 kDa polyfection (initial N/P = 8) on the amount of P3YE5C and
P6YE5C, on complex purification by ultrafiltration (unpurified, solid bars; purified, hatched bars) and on the presence of salt during or after (for purified
complexes) complex formation (black bars, 150 mm sodium chloride; gray bars, no salt). Left, K-562; middle, HepG2; right, NIH-3T3.
Figure 10 (a) PEI-Transferrinfection of K562 cells in the presence of
increasing amounts of P3YE5C. Complexes were prepared at N/P = 8 in
20 mm HEPES pH 7.4 containing 150 mm sodium chloride with or with-
out transferrin–PEI conjugate (corresponding to 1 mg hTf per microgram
DNA). (b) Polylysine polyfection (MDA-MB435S cells) in the presence
or absence of the influenza peptide PROCOP P3INF7 at various pL/DNA
charge ratios.
(Figure 1). The work presented here comprised estab-
lishing a synthetic procedure to derive novel protective
copolymers, the biophysical characterization of copoly-
mer-protected gene vectors and their application in gene
delivery to demonstrate the usefulness of the approach.
The synthetic procedure to derive a reactive copolymer
backbone intermediate (compounds 4 and 5, Figure 2a)
was adapted from previous work by Nathan et al14 who
used copolymers of PEGs and lysine as carriers for
‘small’ molecule drugs. We derived the anionic copoly-
mer end products for use in gene delivery by coupling
the peptides YE5C and INF7 to the reactive backbone
intermediates (Figure 2b). The sequence of the peptide
YE5C ([Ac-YE5]2K-ahx-C) was based on previous work
which demonstrated that at least eight positive charges
are required to achieve efficient DNA binding with
branched cationic peptides.15 We reasoned that in turn at
least the same number of negative charges may be
required for an anionic peptide to bind to a preformed
DNA complex efficiently and decided to use a peptide
with 10 negative charges. For comparison and in order
to derive endosomolytic copolymers, the membrane-
destabilizing peptide INF7 (five negative charges) was
grafted to the copolymer backbone.
The decrease of the zeta potentials as a function of the
amount of PROCOP added to a pre-assembled gene vec-
tor (Figure 4) shows that the copolymers bind to vector
particles. This is in agreement with the recent obser-
vations by Trubetskoy et al16 who show that oppositely
(negatively) charged polyelectrolytes can be deposited on
the surface of condensed DNA particles. With respect to
the results presented by this group, one concern was that
PROCOPs may dissociate DNA complexes by competing
with DNA for binding to the (poly)cation. According to
a gel retardation assay this is not the case. This finding
is further supported by particle size measurements using
dynamic light scattering and electron microscopy which
demonstrate that copolymer-protected polyplexes are
stable particles of remarkably small size (Figure 5 and
Table 1). Importantly, these particles do not aggregate or
flocculate at electrostatic neutrality or upon addition of
salt or serum albumin such as ‘naked’ polyplexes do.
However, PROCOP addition induces a dramatic change
in lipoplex structure (Figure 5d), although neither dis-
sociation nor a reduction of transfection efficiency (data
not shown) are observed. Certainly, these structural
changes are not in favor of applications where a small
particle size is required.
Apart from physical stability of vectors, inertness
towards interaction with serum constituents during the
delivery phase can be desirable, dependent on the target
of gene transfer. While intravenous gene delivery to the
lung with lipoplexes and polyplexes is feasible without
further precautions, other targets such as distant tumors
which require transvascular transport probably afford
small and stable vector particles.17 ‘Naked’ lipoplexes
and polyplexes activate the complement system1
(Figure 6) and bind a number of serum proteins.2,10 While
complement activation does not necessarily have an
impact on biodistribution and efficiency of vectors,18 it is
certainly a matter of concern for applications in humans.
Therefore it is an important achievement that PRO-
COPs reduce or prevent opsonization and complement
activation. This was independently demonstrated by
determining BSA binding using zeta potential measure-
ments (see Results), by examination of general serum
protein binding using a biosensor approach (Figure 7)
and by quantitating the extent of complement activation
using the hemolytic assay (Figure 6). The stoichiometry
of the polycation–DNA core and the molecular weight of
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important parameters governing the extent of opsoniz-
ation and complement activation. Excess PEI is required
for the formation of polyplexes optimized for transfection
efficiency (Figure 8). Surprisingly, at an N/P ratio of 8,
which was the standard composition chosen here, only a
fraction of the PEI is tightly incorporated into the poly-
plex while about half of it can be removed by ultrafiltr-
ation. Important consequences of this procedure are
decreased zeta potentials of the vector formulations
(Figure 4) and complete inhibition of BSA binding and
complement activation (Figure 6) upon addition of PRO-
COPs. Unpurified standard PEI polyplexes were not pro-
tected entirely from BSA binding and complement acti-
vation. Notably, the protective capacity of P6YE5C is
superior to P3YE5C both in the complement assay
(Figure 6a and b) and in biospecific interaction analysis
of general serum protein binding (Figure 7). These
experiments establish that the molecular weight of the
PEG macromonomer in the PROCOP must be greater
than 3400 in order to achieve the maximum protective
effect. For comparison, polylysine polyplexes coated with
the influenza peptide PROCOP P6INF7 were examined.
Also here, PROCOP-dependent prevention of comp-
lement activation was observed (Figure 6c).
In order to be compatible with the intracellular steps
of gene delivery, PROCOPs are designed to dissociate
from the polycation–DNA core at the acidic pH of endo-
somes upon protonation of the glutamic acids. Also,
cleavage of the disulfide bridge between the anionic pep-
tide and the polymer backbone may play a role. Disulfide
exchange reactions during endocytotic uptake of macro-
molecules19 and Sindbis virus20 have been described.
Whatever mechanisms of intracellular vector processing
apply, two opposing effects on transfection efficiency as
a consequence of the effective shielding by PROCOPs
could be envisaged for gene delivery: (1) an inhibitory
influence due to the loss of cell binding capacity; (2) an
enhancing effect due to reduced toxicity based on mask-
ing of excess positive charge of vectors and due to the
integrity of vector particles towards opsonization by
serum (all transfections were carried out in serum-con-
taining medium).
Probably due to loss of cell binding capacity, an inhibi-
tory influence of PROCOPs was observed at the lower
N/P ratios (4 and 6; Figure 8) where toxicity of naked
vectors is not limiting. Their toxicity becomes more pro-
nounced at higher N/P ratios, hence the toxicity-reduc-
ing coating with PROCOPs counterbalances the loss of
cell binding capacity, and transfection levels remain
unchanged. Vectors prepared in salt-containing buffers
aggregate and sediment on cells in culture, giving rise to
increased transfection efficiency,21 particularly with
adherent cell lines (Figure 9). However, the toxicity of
such aggregates is most striking, explaining the strong
improvement in transfection by the toxicity-reducing
PROCOPs (toxicity can be assessed from the protein con-
tent of cell extracts after transfection which in fact was
up to three-fold higher when the polyplexes were coated
with PROCOPs). If in addition the loss of cell binding
capacity is compensated for by a receptor ligand as part
of the vector, highest expression levels are achieved
(Figure 10a). The versatility of the synthetic design of
PROCOPs is again demonstrated with the compounds
P3INF7 and P6INF7. These compounds display the
Gene Therapy
desired membrane-destabilizing activity (Figure 3),
inhibit particle aggregation and complement activation
(examined for P6INF7, Figure 6c) and enhance the trans-
fection efficiency of polylysine–DNA (examined for
P3INF7, Figure 10b).
The data presented show that essential characteristics
of nonviral gene vectors (particle size, charge, suscepti-
bility to opsonization and toxicity) can be controlled with
the help of PROCOPs without impairing gene transfer
efficiency. The modular design of the synthetic procedure
and of the vector assembly will greatly facilitate a sys-
tematic optimization towards successful gene delivery
in vivo.
Materials and methods
Reagents
Chemicals were purchased from Sigma/Aldrich/Fluka
(Deisenhofen, Germany) if not otherwise stated. Amino
acid derivatives and resins for peptide synthesis were
purchased from Bachem (Heidelberg, Germany). 1,2-
dioleoyl-3-trimethylammoniumpropane (DOTAP) was
purchased from Avanti Polar Lipids (Alabaster, AL,
USA). LipofectAMINE was purchased from Life Techno-
logies (Eggenstein, Germany). Cell culture media were
purchased from Biochrom KG (Berlin, Germany). The
plasmid pCMVLuc was a kind gift from Ernst Wagner
(Boehringer Ingelheim, Vienna, Austria). PEI 25 kDa
(Aldrich) was used throughout the study for PEI poly-
plex formation.
PROCOP synthesis
3-(29-thio-pyridyl)-mercaptopropionyl-glutamic acid: One
gram of 2,29-dithiodipyridine (DTDP) dissolved in 4 ml
ethanol was reacted with 87 ml (1 mmol) 3-mercaptopro-
pionic acid in the presence of 100 ml triethylamine. After
1 h, excess DTDP was precipitated by the addition of
water. The supernatant was separated by reverse phase
HPLC (gradient elution 0.1% trifluoro acetic acid/0–40%
acetonitrile in 24 min; flow rate 25 ml/min. Column:
Vydac 218TP1022). Lyophilized product (0.5 mmol) was
dissolved in 25 ml dichloromethane, cooled on ice fol-
lowed by addition of 1 mmol each of glutamic acid-
di-t-butyl ester, 1-hydroxybenzotriazole, N-ethyl-N ¢ -
(dimethylaminopropyl)-carbodiimide and diisopropyl-
ethylamine. After 48 h reaction at room temperature and
removal of the solvent by rotary evaporation the oily resi-
due was taken up in 20 ml ethyl acetate. This solution
was extracted twice each with 0.5 m hydrochloric acid,
saturated sodium bicarbonate solution and saturated
sodium chloride solution. The organic phase was evapor-
ated on a rotary evaporator, and the oily residue dried
under high vacuum. Without further purification the
product was treated for 2 h with 30 ml dichloro-
methane/TFA (2:1) for removal of the t-butyl protecting
groups followed by removal of the solvent by rotary
evaporation. The residue was treated with ice-cold ether
and dried in vacuo. The product was dissolved in 20 mm
HEPES pH 7.4 and purified by reverse phase HPLC
(conditions as above). Pooled product fractions were
lyophilized. Product identity was confirmed by mass
spectroscopy (calculated 345.06; observed 345,0 (MH+)).
The overall yield was 27%.
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Copolymerization of 3-(2 ¢ -thio-pyridyl)-mercaptopropionyl-
glutamic acid (3) with O,O ¢ -Bis(2-aminoethyl)
poly(ethylene glycol) 3400 or -6000 (diamino-PEG-3400
or 6000): Product 3 was dissolved in 3 ml dimethyl for-
mamide and diluted to 20 ml with dichloromethane. To
5 ml (67.5 mmol compound 3) of this solution 1.25 equiva-
lents of diamino-PEG-3400 (or - 6000, respectively), 30 mg
dicyclohexylcarbodiimide (135 mmol, 2 equivalents) and
2 mg dimethylaminopyridine (0.25 equivalents) were
added. After 2 h reaction at room temperature raw pro-
ducts (4) and (5) were obtained by precipitation with t-
butyl-methyl-ether on ice and dried in vacuo. Aliquots of
20 mg were dissolved in HBS and purified by gel per-
meation chromatography after removal of unsoluble
material by ultrafiltration (chromatography: Superdex 75
material filled in a Pharmacia XK 16/40 column
(Freiburg, Germany)). Flow rate 1 ml/min with 20 mM
HEPES pH 7.4 as eluent, optionally containing 150 mm
sodium chloride). The main fractions eluted with an
apparent molecular weight of 22.8 kDa (PEG-3400 poly-
mer, ‘P3-TP’) and 40 kDa (PEG-6000 polymer, ‘P6-TP’),
respectively, preceded by minor overlapping higher mol-
ecular weight peaks that have not been used for sub-
sequent studies (Figure 2).
Peptide synthesis
Peptide synthesis was carried out using a chlorotrityl
chloride resin (Bachem, Heidelberg, Germany) and
applying a modified FastMoc protocol on an Applied
Biosystems (Weiterstadt, Germany) 431A automated pep-
tide synthesizer. The purified branched peptide YE5C
(sequence (Ac-YE5)2K-ahx-C; ahx = 6-aminohexanoic
acid) was obtained by reverse phase chromatography as
described above. Lyophilized product was dissolved in
water upon dropwise addition of 1 m sodium carbonate.
Peptide INF7 (GLFEAIE FGIENGWEGMIDGWYGC) was
obtained in a similar manner and purified by gel filtration
(Sephadex G10 filled in a Pharmacia HR 10/30 column,
flow rate 1 ml/min with 20 mm ammonium bicarbonate
pH 8 as eluent). Peptide identity and the absence of
byproducts were confirmed by mass spectroscopy
(electrospray/ion trap; Thermo Quest–LCQ, Egelsbach,
Germany).
Coupling of peptides to copolymers P3-TP and P6-TP
Copolymer solutions were added to a 1.2-fold excess
(thiol over thiopyridyl groups) of peptide solutions in
20 mm HEPES pH 7.4 and reacted overnight at room tem-
perature. Completeness of reactions was confirmed by
measuring the absorbance of released thiopyridone at
342 nm (extinction coefficient 8080 m - 1 cm - 1). Reaction
products were purified by size exclusion chromato-
graphy (Superdex 75 filled in a Pharmacia XK 16/40
column; conditions as described above). Copolymeric
peptide concentrations were determined by measuring
the absorbance at 280 nm in 6 m guanidinium
hydrochloride/20 mm sodium phosphate buffer pH 6.5
using calculated extinction coefficients22 of 2560 m- 1 cm- 1
for YE5C and 12660 m - 1 cm - 1 for INF7.
Erythrocyte lysis assay
Serial dilutions (1.5-fold) of the compound under con-
sideration were carried out in U-bottom 96-well plates by
transferring 100 ml out of 150 ml solution in column 1 to
50 ml buffer in column 2, mixing and so on, similarly as
described previously1 for the complement assay. The
examined compounds were dissolved and dilutions were
carried out in 20 mm HEPES/150 mm sodium chloride
pH 7.4 or in 10 mm sodium citrate/150 mm sodium chlor-
ide pH 5, respectively. Human erythrocytes (3 · 106) in
150 ml of HEPES or citrate buffer, respectively, were
added, and the plate was shaken at 400 r.p.m. in a Series
25 Incubator Shaker (New Brunswick Scientific Co, NJ,
USA) for 1 h at 37 ° C. After centrifugation at 2000 g, 150 ml
supernatant was transferred to flat-bottom 96-well plates,
and relative hemoglobin concentrations were measured
at 405 nm using an ELISA plate reader (Biolumin 960,
Molecular Dynamics, Krefeld, Germany).
Assay for human complement activation
Stock solutions of 191.4 mg plasmid DNA (pCMVLuc) per
milliliter were mixed with stock solutions of 200 mg PEI
per milliliter in 20 mm HEPES pH 7.4. Aliquots of 610 ml
of the resulting complexes were added to 305 ml solutions
of 0, 1, 2 and 3 charge equivalents of P3YE5C and
P6YE5C, respectively, in 20 mm HEPES pH 7.4. Charge
equivalents refer to the amount of polymeric peptide in
terms of negative charges as multiples of the negative
charges of DNA in the complex. After addition of 101.7 ml
of 50% glucose to each sample, 150 ml each
(corresponding to 8.6 mg DNA and 9 mg PEI) were dis-
tributed to column 1 of a 96-well plate. A 1.5-fold dilution
series and the complement assay were carried out as
described.1
In the same manner purified PEI–DNA stock solutions
of 21.7 mg DNA per ml were added to 0, 1, 2 and 3 charge
equivalents of P6YE5C in 305 ml each, respectively.
Before distribution of 150 ml aliquots to 96-well plates for
the dilution series, samples were adjusted to 150 mm
sodium chloride.
Also, a polylysine–DNA polyplex stock solution was
prepared from pL170 (Sigma; average chain length 170;
256 mg in 800 ml HBS) and the plasmid pCMVLuc (64 mg
in 800 ml HBS), corresponding to a calculated charge ratio
of 6.3. Aliquots of 350 ml were incubated with 0, 35, 70
and 105 nmol of polymer-bound peptide INF7 (‘P6INF7’)
and filled up to 1050 ml with GVB2+ buffer after 15 min
of incubation. Aliquots of 150 ml each were added to col-
umn 1/A-F of a round-bottom 96-well plate. The comp-
lement activation assay was then carried out as
described.
Biosensor studies of the interaction between PEI–DNA
complexes and human serum proteins
To evaluate the interactions of DNA complexes and
human serum proteins, surface plasmon resonance
measurements were performed using a biosensor
approach (BIAcore, Uppsala, Sweden). Human comp-
lement serum (Sigma) was covalently attached to the sur-
face of a research grade carboxymethyl dextran chip
(CM5) according to the standard protocol.7 Briefly, after
N-(3-dimethylaminopropyl)-N¢ -ethyl-carbodiimide/N-hy-
droxysuccinimide activation of the caboxyl groups, the
serum dilution (100 mg/ml in 10 mm sodium acetate
pH 4) was injected and residual N-hydroxysuccinimide
esters were inactivated by injection of 1 m ethanolamine
pH 8.5 in water. The immobilization procedure and the
binding studies were performed at 25° C with 10 mm
HEPES pH 7.4/150 mm sodium chloride/3.4 mm
EDTA/0.05% Surfactant P20 as continuous flow buffer at
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prepared in 20 mm HEPES pH 7.4 at final DNA concen-
trations of 10 mg/ml as described below for transfections.
Immediately before injection, sodium chloride was added
automatically to a concentration of 150 mm. DNA com-
plexes were injected twice for 4 min followed by washes
with running buffer until the signal stabilized (flow rate
of 5 ml/min).
Particle size and zeta potential measurements
PEI polyplexes (N/P = 8) were prepared by mixing 40 mg
DNA (pCMVLuc) and 41.7 mg PEI (25 kDa, Aldrich) each
dissolved in 333 ml 20 mm HEPES pH 7.4. After 15 min
of incubation 0, 0.5, 1, 1.5, 2 or 3 charge equivalents of
PROCOPs P3YE5C or P6YE5C in 333 ml HEPES were
added (corresponding to 0, 152, 303, 455, 606 and
909 pmol of peptide). DOTAP/cholesterol lipoplexes
were prepared similarly by mixing 333 ml each of 40 mg
of DNA and 5 charge equivalents of a 5 mm
DOTAP/cholesterol liposome suspension in 20 mm
HEPES pH 7.4. PROCOPs were added as described for
PEI–DNA. DOTAP/cholesterol (1:1 mol/mol) liposomes
were prepared essentially as described.23
The particle sizes were determined by dynamic light
scattering (using a Zetamaster 3000, Malvern Instru-
ments, Herrenberg, Germany) at various time-points after
complex formation and by electron microscopy as
described previously.24 Zeta potentials of the same
samples were determined using the Malvern Zetamaster
with refractive index, viscosity and dielectric constant
parameters set to those of water as an approximation.
Purification of DNA complexes
Stock solutions of PEI polyplexes (N/P = 8; 100 mg DNA
per milliliter in 20 mm HEPES pH 7.4) were centrifuged
through Centricon-100 membranes (Millipore, Eschborn,
Germany) four times 15 min at 500 g on a Beckman JA-
20 fixed angle rotor. Between centrifugations the polyplex
solutions were rediluted to the original concentrations.
Care was taken not to exceed DNA concentrations of
500 mg per ml. The final centrifugation yielded poly-
plexes of 300–500 mg DNA per milliliter. The DNA con-
centration was determined by its absorbance at 260 nm
(1 OD260 = 45 mg/ml for dsDNA in a PEI–DNA complex
as determined from a standard dilution of a DNA com-
plex of known DNA content). The amount of free, not
DNA-associated PEI was determined in the combined
filtrates by a trinitrobenzesulfonic acid assay.25
Cell culture and transfections
K-562 cells (human lymphoblasts; ATCC No. 45506), Hep
G2 (human hepatoblastoma; ATCC No. HB-8065), the
human breast cancer cell line MDA-MB435S (ATCC
No. 45526) and NIH-3T3 mouse fibroblasts (DSMZ
No. ACC 59) were grown at 37 ° C in an atmosphere of 5%
CO2 in DMEM supplemented with 10% fetal calf serum,
100 units/ml penicillin, 100 mg/ml streptomycin and
2 mm glutamine. Cells were seeded in 96-well plates at
densities of 20 000–50 000 cells per well the day before
transfection. For transfection, 150 ml of fresh medium
were added and DNA complexes were added in a vol-
ume of 50 ml. Transfections were carried out in triplicates.
Preparation of polyplexes for transfections
For cell culture experiments polyplexes were prepared as
stock solutions in 20 mm HEPES buffer pH 7.4 (with or
Gene Therapy
without 150 mm sodium chloride or 5% glucose as indi-
cated in the Figure legends), where each component
(DNA, polycation, PROCOP) was dispensed in an equal
volume to result in a final amount of 1 mg DNA per 50 ml
which was the amount added to the cells in each well
(same amounts of DNA complex in the same volume and
buffer were also added in the case of purified
polyplexes). First, DNA was added to the polycation with
mild vortexing or mixing with the pipet, after 15 min
PROCOP was added and after a further 30 min or more,
polyplexes were added to the cells. A transferrin–PEI
conjugate with one transferrin molecule per PEI molecule
was prepared essentially as described.26 For most studies,
PEI polyplexes8 were used at an N/P ratio of 8.
Luciferase assay
Twenty-four hours after transfection, cells were washed
once with PBS and then incubated with 100 ml of lysis
buffer (0.1% Triton X-100 in 250 mm Tris pH 7.8). Ten to
50 ml each of the cell lysates were transferred to black 96-
well plates, mixed with 100 ml of luciferin buffer (60 mm
dithiothreitol, 10 mm magnesium sulfate, 1 mm ATP,
30 mm D ( - )-luciferin, in 25 mm glycyl-glycine pH 7.8)
and assayed for bioluminescence using a TopCount
instrument (Canberra Packard, Groningen, The
Netherlands). The protein content of the cell lysates was
determined using the BioRad protein assay adapted for
use in a 96-well plate format. Specific luciferase activity
in nanograms luciferase per milligram of protein were
calculated from a calibration curve which was obtained
from the luminescence of a serial dilution of luciferase
(Roche, Mannheim, Germany).
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